For example, beta-blockers with different β1AR:β2AR selectivity may have different actions at progressive stages of HF development.52 This could conceivably maintain β2AR localization and the native spatial restriction of β2AR signalling, and may represent a new potential therapeutic avenue. The gene discussed is ADRB1; the disease is hydrops fetalis.